



Form PTO-1449 (Rev. 2-32) U.S. Department of Commerce Patent and Trademark Office					Atty. Docket No. LAY-006CIA		Serial No. 09/494,088	
Information Disclosure Statement by Applicant					Applicant: <del>Allison E. Willing et al.</del> <b>McGrogan</b>			
(Use several sheets if necessary)					Filed: January 28, 2000 Group: 1632			
U.S. Patent Documents								
Init.		Document No.	Date	Name	Class	Subclass	Filing Date	
							RECEIVED	
							APR 14 2003	
							TECH CENTER 1600/2900	
Foreign Documents								
Init.		Document No.	Date	Country	Class	Subclass	Translation Yes No	
Am2	1	WO 90/06757	06/28/1990	PCT (US)	A61K	35		X
	2	WO 94/10292	05/11/1994	PCT (US)	C12N	5/06		X
↓	3	WO 96/15224	05/23/1996	PCT (US)	C12N	5/00		X
Am2	4	WO 97/33470	09/18/1997	PCT (US)	A01N	1/00		X
Other Documents (Including Author, Title, Date, Pertinent Pages, etc.)								
Am2	5	S. J. Pleasure et al., "Pure, Postmitotic, Polarized Human Neurons Derived from Ntera 2 Cells Provide a System for Expressing Exogenous Proteins in Terminally Differentiated Neurons", <u>Jr. of Neuroscience</u> , Vol. 12, No. 5, pp. 1802-1815, May 1992						
	6	T. Terao et al., "Lithium Chloride Stimulates Catecholamine Synthesis and Secretion in Cultured Bovine Adrenal Medullary Cells", <u>Bio. Psychiatry</u> , Vol. 31, No. 10, pp. 1038-1049, 1992 (no month)						
↓	7	M. Mena et al., "Effects of Dibutyryl Cyclic AMP and Terinoic Acid on the Differentiation of dopamine Neurons: Prevention of Cell Death by Dibutyryl Cyclic AMP", <u>Journal of Neurochemistry</u> , Vol. 65, No. 6, 2612-2620, 1995 (no month).						
Am2	8	Layton BioScience Press Releases, No. 24, March 9, 1999; No. 25, February 15, 1999; No. 26, February 5, 1999; No. 27, February 5, 1999; No. 28, February 4, 1999; No. 29, February 1, 1999; No. 30, December 1, 1998; No. 31, December 1, 1998; reprinted [Internet] <a href="http://www.laytonbio.com/whatsnew.htm">http://www.laytonbio.com/whatsnew.htm</a> .						
Examiner <b>Anne-Marie Falk</b>					Date Considered <b>7/17/03</b>			
Examiner: Initial if citation considered, whether or not citation is in conference with MPEP 609; Draw line through citation if not conformance and not considered. Include a copy of this form with the next communication to applicant.								